Mometasone Zentiva (Mometasone Furoate Monohydrate)

Mometasone furoate binds to glucocorticoid receptors in the cells lining the nasal passages. This binding alters gene expression, suppressing the production of inflammatory mediators and decreasing immune‑cell infiltration, which leads to reduced nasal inflammation and symptom relief.

The exact dose is determined by the prescribing clinician based on the patient’s age, severity of symptoms, and response to therapy. Typical regimens involve one or two sprays per nostril once daily, but the prescriber sets the final dosing schedule.

Safety data for mometasone furoate in pregnancy are limited, so it should only be used if the potential benefit outweighs any risk. During breastfeeding, the drug may be present in milk; mothers should discuss possible risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometasone furoate is a high‑potency intranasal corticosteroid with a low systemic bioavailability, offering strong local anti‑inflammatory effects while minimizing systemic exposure. Compared with agents such as fluticasone or budesonide, it provides comparable efficacy with a similar safety profile, though individual response may vary.

Store the nasal spray at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from moisture, direct sunlight and extreme heat. Keep the device upright and avoid freezing. Do not share the product with others.

The spray is administered directly into each nostril. Before use, gently shake the bottle, prime it if required, and tilt the head slightly forward. Insert the tip into a nostril, close the opposite nostril, and press the actuator to deliver the prescribed number of sprays. Avoid blowing the nose immediately after administration.

Serious risks, though rare, include adrenal suppression with prolonged high‑dose use, fungal infections of the nasal mucosa, severe nosebleeds, and systemic immunosuppression that could increase susceptibility to infections. Patients should report persistent bleeding, visual changes, or signs of infection to their healthcare provider promptly.

Mometasone Zentiva should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active, untreated fungal infections of the nasal passages or those who have recently undergone nasal surgery without medical clearance.